Increased scope to explore additional cohorts of Opdivo (nivolumab) plus lirilumab in solid tumors, including a cohort exploring Opdivo with or without lirilumab in squamous cell carcinoma of the head...

Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m)...

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces...

The study did not meet the primary efficacy endpoint Study confirms the safety profile of lirilumab as a monotherapy Broad clinical program ongoing, investigating lirilumab in a variety of tumor...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that, per the licensing agreement for lirilumab, Bristol-Myers Squibb has paid Innate Pharma a US$15 million...

Preliminary data from the dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with Sezary syndrome; IPH4102 shows good safety...

Cash, cash equivalents and financial assets amounting to €239.6 million [1] Continued progress with key clinical trials Safety data for lirilumab in combination in Phase I studies presented at the...

Abstract now available online - More data in oral presentation on November 12 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces the publication of the late-breaking...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent...

Objective response rate (ORR) was 24% in 29 evaluable patients and increased in inflamed (PD-L1 positive) tumors, with ORR of 41% in patients with > 1% PD-L1 expression No significant added toxicity...